Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Synlogic Inc SYBX

Healthcare Biotechnology
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non... see more

Recent & Breaking News (NDAQ:SYBX)

Synlogic Reports Third Quarter 2024 Financial Results

GlobeNewswire November 12, 2024

Synlogic Reports Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Synlogic Reports First Quarter 2024 Financial Results

GlobeNewswire May 14, 2024

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 19, 2024

Synlogic Adopts Limited Duration Stockholders Rights Plan

GlobeNewswire February 20, 2024

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

GlobeNewswire February 8, 2024

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

GlobeNewswire February 2, 2024

Synlogic Provides Corporate Update and Outlook for 2024

GlobeNewswire January 4, 2024

Synlogic Announces Contract with the Air Force Research Lab

GlobeNewswire December 27, 2023

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

GlobeNewswire December 7, 2023

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2023

Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration

GlobeNewswire November 7, 2023

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

GlobeNewswire October 3, 2023

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

GlobeNewswire September 29, 2023

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

GlobeNewswire September 28, 2023

Synlogic Announces Reverse Stock Split

GlobeNewswire September 27, 2023

Synlogic to Participate in Chardan's Genetic Medicines Conference

GlobeNewswire September 21, 2023

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

GlobeNewswire September 19, 2023

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 10, 2023

Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

GlobeNewswire July 11, 2023